Michael Attubato, MD
Interventional Cardiology · New York, NYNPI 1619963915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,313 of the $35,348 with a category attached, or 85.8%. 13 manufacturers reported payments, led by Boston Scientific at 55.2% of the total.
Across 145 payments — averaging $243.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$20K
- Medtronic$13K
- Welch Allyn$766
- Endologix LLC$638
- Abbott$461
- Penumbra, Inc.$224
- plus $432 from 7 others
Across 42 payments — averaging $7125.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$230K
- Penumbra, Inc.$61K
- Boston Scientific$6K
- Philips North America LLC$2K
- Abbott$45
What the payments were for
- Speaking & faculty fees$30,31386%
- Food & beverage$4,27012%
- Other$7662%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 72 | $19,526 |
| Medtronic(2 entities) | 22 | $13,302 |
| Welch Allyn | 1 | $766 |
| Endologix LLC | 4 | $638 |
| Abbott | 22 | $461 |
| Penumbra, Inc. | 13 | $224 |
| Recor Medical Inc | 1 | $186 |
| Shockwave Medical, Inc | 3 | $71 |
| Abiomed | 2 | $57 |
| Asahi Intecc USA, Inc. | 2 | $40 |
| Bayer | 1 | $31 |
| Amgen | 1 | $31 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$12,500
- JETSTREAM$5,000
- GENERAL VASCULAR INTERVENTION$4,063
- GENERAL ATHERECTOMY$3,750
- ELUVIA$2,667
- OPTICROSS$2,500
- NONE$766
- Torus Stent Graft System$482
- ENDOCROSS Device$482
- TurboHawk$420
- PARADISE RENAL DENERVATION SYSTEM$186
- CROSSBOSS$140
How this compares
$35,348 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.